North West Cancer Centre, Altnagelvin Hospital, Western Health and Social Care Trust, Derry, UK.
Ulster University, Londonderry, UK.
J Med Radiat Sci. 2023 Dec;70(4):424-435. doi: 10.1002/jmrs.711. Epub 2023 Aug 7.
Over 60 % of people who develop breast cancer will receive radiation therapy (RT) as part of their treatment. Side effects of RT may include inflammation, erythema, desquamation and fatigue. Electronic Patient Reported Outcomes Measures (ePROMs) enable patients to report side effects prior to their scheduled post-RT appointment. This pilot service evaluation aims to explore patients' perceptions regarding the value of the ePROM system, ease of its use and barriers to using the system, after breast irradiation.
From July-November 2021, evaluation surveys were posted to 100 people who had received RT to their breast to explore their experience of using the ePROM. Ethical approval was obtained through Ulster University and the Western Health and Social Care Trust (WHSCT), Northern Ireland.
Fifty-two people responded to the survey, of which 27 respondents indicated that they had accessed the ePROM. Despite few participants experiencing significant side effects, the majority of participants recommended the ePROM indicating that it was an important source of support. Those who experienced significant side effects found the system to be prompt and effective. Barriers to accessing the ePROM included technical issues with the link, concerns about confidentiality and forgetting to access the link. Access to the ePROM increased with higher education levels.
This pilot service evaluation demonstrated that ePROMs are valued by patients and can provide rapid real-time access to support, offering individual care and reassurance. For patients with longer RT schedules (>10 fractions), the introduction of ePROMs during RT was viewed favourably by participants. All patients may benefit from the option of receiving ePROMs post-RT.
超过 60%的乳腺癌患者将接受放射治疗(RT)作为其治疗的一部分。RT 的副作用可能包括炎症、红斑、脱屑和疲劳。电子患者报告结局测量(ePROMs)使患者能够在预定的 RT 后预约前报告副作用。本试点服务评估旨在探讨患者在接受乳房放疗后对 ePROM 系统价值、使用便利性以及使用系统障碍的看法。
2021 年 7 月至 11 月,向 100 名接受过乳房 RT 的患者发布了评估调查,以探讨他们使用 ePROM 的体验。伦理批准通过阿尔斯特大学和北爱尔兰西部卫生和社会保健信托(WHSCT)获得。
52 人对调查做出了回应,其中 27 名受访者表示他们已经访问了 ePROM。尽管很少有参与者经历明显的副作用,但大多数参与者建议使用 ePROM,表明它是一个重要的支持来源。那些经历过明显副作用的人发现该系统既迅速又有效。访问 ePROM 的障碍包括链接的技术问题、对保密性的担忧以及忘记访问链接。受教育程度较高的人更容易访问 ePROM。
本试点服务评估表明,ePROMs 受到患者的重视,能够提供快速实时的支持,提供个性化的护理和安慰。对于 RT 计划较长(>10 个部分)的患者,参与者对 RT 期间引入 ePROMs 持赞成态度。所有患者可能都受益于接受 RT 后接受 ePROMs 的选择。